Connect with us

Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. Read More

More in NOLA POLITICS